Article Text

PDF
Response to: ’Checkpoint inhibitor-induced polymyalgia rheumatica controlled by cobimetinib, a MEK 1/2 inhibitor' by Chan and Bass
  1. Marie Kostine1,
  2. Léa Dousset2,
  3. Thierry Schaeverbeke1
  4. on behalf of the FHU-ACRONIM
  1. 1Department of Rheumatology, Centre Hospitalier Universitaire de Bordeaux, Bordeaux, France
  2. 2Department of Dermatology, Centre Hospitalier Universitaire de Bordeaux, Bordeaux, France
  1. Correspondence to Dr Marie Kostine, Department of Rheumatology, Centre Hospitalier Universitaire de Bordeaux, Bordeaux 33000, France; marie.kostine{at}chu-bordeaux.fr

Statistics from Altmetric.com

We read with genuine interest the original case reported by Chan and Bass1 in response to our paper describing musculoskeletal immune-related adverse events (irAE) related to cancer immunotherapy.2

Immune checkpoint inhibitors (ICI) represent an exciting new standard of care in selected advanced cancers and are being actively investigated in others. Unfortunately, only a subset of patients benefit from ICI and the current challenge is to transform the majority of non-responders to responders.3 This will likely be improved by combining ICI with other treatment strategies such as small molecules.

Two MEK inhibitors, trametinib and cobimetinib, are …

View Full Text

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Linked Articles